The phase 3 clinical trial evaluating use of tirzepatide — the drug’s generic name — injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction and obesity. The trial lasted for 52 weeks.
The study found patients on Mounjaro injections were less likely to be hospitalized, less likely to increase their heart failure medication or die of heart complications, and had fewer symptoms such as shortness of breath, fatigue, and swelling of the lower legs, according to an Aug. 1 company news release.
The results have not been peer reviewed.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
